[1] 赫捷, 陈万青. 中国肿瘤登记年报(2012). 北京:军事医学科学出版社,2012: 27- 60.
[2] Yang S, Luo C, Gu Q, et al. Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma.Oncotarget, 2016, 7: 5461-5469.
[3] 程兮,邱伟华. 肝癌合并门静脉癌栓的多学科治疗进展.外科理论与实践, 2015, 20: 360-363.
[4] Mohamad B, Shah V, Onyshchenko M,et al. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis. Hepatol Int, 2016, 10: 632-639.
[5] Yopp AC, Choti MA. Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma: A Growing Epidemic Dig Dis, 2015, 33: 642-647.
[6] Niessen C, Thumann S, Beyer L, et al. Percutaneous Irreversible Electroporation: Long-term survival analysis of 71 patients with inoperable malignant hepatic tumors. Sci Rep, 2017, 7: 43687.
[7] Zhou M, Wang S, Hu L, et al. miR-199a-5p suppresses human bladder cancer cell metastasis by targeting CCR7. BMC Urol, 2016, 16: 64.
[8] Mishan MA, Ahmadiankia N, Bahrami AR. CXCR4 and CCR7: Two eligible targets in targeted cancer therapy. Cell Biol Int, 2016, 40: 955-967.
[9] Jang CW, Kwon HJ, Kong H, et al. Impact of clinically significant portal hypertension on surgical outcomes for hepatocellular carcinoma in patients with compensated liver cirrhosis: a propensity score matching analysis. Ann Hepatobiliary Pancreat Surg, 2016, 20:159-166.
[10] Yang Y, Chen L, Gu J, et al. Recurrently deregulated lncRNAs in hepatocellular carcinoma. Nat Commun, 2017, 8:14421.
[11] Hong H, He C, Zhu S, et al. CCR7 mediates the TNF-α-induced lymphatic metastasis of gallbladder cancer through the "ERK1/2 - AP-1" and "JNK - AP-1" pathways. J Exp Clin Cancer Res, 2016, 35: 51.
[12] Sun L, Zhang Q, Li Y, et al. CCL21/CCR7 up-regulate vascular endothelial growth factor-D expression via ERK pathway in human non-small cell lung cancer cells. Int J Clin Exp Pathol, 2015, 8: 15729-15738. |
